Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

December 12, 2018

Follow-up Trial Results Reinforce Yescarta as Relapsed Non-Hodgkin’s Lymphoma Therapy

News

More than two years after receiving treatment with Yescarta (axicabtagene ciloleucel), 51% of non-Hodgkin’s lymphoma patients included in the ZUMA-1 Phase 1/2 clinical trial are still alive, and 39% ... Read more

December 5, 2018

5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients

News

A combination of Forty Seven‘s macrophage checkpoint inhibitor Hu5F9-G4 and Rituxan (rituximab) is safe and completely eliminated tumors in one-third of non-Hodgkin’s lymphoma patients included in a Phase 1b trial. The ... Read more

December 4, 2018

Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration has approved Truxima (rituximab-abbs), a biosimilar to Rituxan (rituximab), for three CD20-positive non-Hodgkin’s lymphoma indications, Celltrion and Teva announced. The decision comes less than two months after the FDA’s Oncologic ... Read more

December 3, 2018

Poteligeo Approved in Europe for 2 Forms of Cutaneous T-cell Lymphoma

News

The European Commission approved the use of Poteligeo (mogamulizumab) for patients with mycosis fungoides or Sézary syndrome — the most common cutaneous T-cell lymphomas — who failed at least one prior systemic therapy. The approval ... Read more

November 26, 2018

Phase 1 Study of BTK Inhibitor in Treating B-cell Blood Cancers Underway, TG Therapeutics Announces

News

A Phase 1 clinical trial, sponsored by TG Therapeutics, is recruiting patients with B-cell lymphoma or leukemia to study the company’s Bruton tyrosine kinase (BTK) inhibitor, TG-1701. The study is enrolling ... Read more

November 20, 2018

Adcetris-Chemo Combo Gets FDA Approval for First-line Treatment of PTCL

News

The U.S. Food and Drug Administration (FDA) approved Seattle Genetics‘ application requesting that Adcetris (brentuximab vedotin) be used in combination with chemotherapy as a first-line treatment for systemic anaplastic large ... Read more

November 16, 2018

Opdivo Plus ASCT Ably Treats Classical Hodgkin’s Lymphoma Patients with Few Options, Study Says

News

Classical Hodgkin’s lymphoma patients who failed to respond to autologous stem cell transplant (patient-derived cells) showed “unprecedented” low relapse rates after being given Opdivo (nivolumab) followed by an allogeneic, or ... Read more

November 13, 2018

Rituxan Shows Similar Benefit With or Without Chemo in Indolent Lymphomas, Study Finds

News

Using Rituxan (rituximab) as first-line treatment for indolent — or slow-growing — lymphomas leads to similar long-term survival as regimens containing both Rituxan and chemotherapy, a study shows. The approach also ... Read more

November 12, 2018

FDA Gives Selinexor Fast Track Status for DLBCL Treatment

News

The U.S. Food and Drug Administration has granted fast track status to Karyopharm Therapeutics‘ investigational oral therapy selinexor for people with diffuse large B-cell lymphoma (DLBCL) who have received two or ... Read more

November 6, 2018

Adcetris as Stem Cell Transplant Consolidation Therapy Delays Hodgkin’s Progression in Long-term, Data Show

News

Patients with classical Hodgkin’s lymphoma who are at high risk of progressing after a stem cell transplant may benefit significantly from Adcetris (brentuximab vedotin) consolidation treatment in the long-term, researchers ... Read more

Pin It on Pinterest